statementSaid on 2026-11-11
After acquiring a controlling stake in Green Valley Pharmaceutical, Fosun incorporated sodium oligomannate capsules, used for mild to moderate Alzheimer's disease, into its innovative drug pipeline and took over its post-marketing confirmatory clinical study.
A statement by post author, said on 2026-11-11. Statements are as reported by the cited publishers — not verified by DecisionGateway.
復星通過併購直接切入已上市產品,控股收購綠谷醫藥後,將用於輕至中度阿爾茨海默病的甘露特鈉膠囊納入創新藥管線,並承接其上市後確證性臨床研究。
Discussion
Related claims
The self-developed SHR-3201 injection has been approved by the National Medical Products Administration to conduct clinical trials, and it is intended for Alzheimer's disease.post author · statementSimcere Pharmaceutical has partnered with Germany's Vivoryon to develop SIM0408 in China, targeting neurotoxic amyloid N3pE, and it has been approved by the CDE to enter clinical trials.post author · statementXinhua Pharmaceutical's OAB-14 dry suspension has completed enrollment of the first patient in China for Phase II clinical trials; Gaoguang Pharmaceutical's brain-penetrant TYK2/JAK1 inhibitor TLL-041 is positioned as a neurodegenerative disease candidate with global first-in-class potential.post author · statementLY03017 for psychotic disorders associated with Alzheimer's disease has entered Phase II clinical trials in China and completed first dosing; LY03020, as the world's first TAAR1/5-HT2CR dual-target agonist, also lists psychotic disorders associated with Alzheimer's disease as a target indication.post author · statement霈方目前已自主研發逾250項產品,供應鏈合作夥伴遍及全球18個以上國家,並推出細胞外囊泡修護品牌「泌力ExoPower」,切入醫美術後居家保養市場。post author · statementNovartis's expensive gene therapy has been reported to carry a cancer risk.解药 · allegation